Dr. Ghosh on PET-Adapted Therapy in Patients With Hodgkin Lymphoma

Video

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses PET-adapted therapy in patients with Hodgkin lymphoma.

PET-adapted therapy has been referenced for the past 5 to 7 years in Hodgkin lymphoma. It has been used in multiple clinical trials. The reason, states Ghosh, is that more than a decade ago a paper was published that showed that patients with a positive PET scan after 2 cycles of ABVD had poor outcomes. Patients who had a negative PET scan had much better outcomes, states Ghosh.

Many clinical trials were designed to look at ways to improve the outcomes of patients with positive PET outcomes. These patients were dose escalated. One trial used the regimen IGEV followed by autologous transplant. In these trials, patients with positive PET outcomes had a progression-free survival (PFS) in the 60% to 70% range, whereas patients with negative PET outcomes had a PFS in the 80% to 85% range, states Ghosh.

Related Videos
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD
James Knight, MD
Jason Efstathiou, MD, DPhil